VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont) Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040s Neurocrine to H

Funding led by TK Partners supports further clinical validation, regulatory preparation, and commercialization of OncoGaze™ April 2, 2026 -- Acurion, a precision oncology technology company advancing AI-driven cancer biomarker detection through its OncoGaze™ platform, today announced the closing of its oversubscribed seed financing round, raising $4.3 million against a $4 million target. The round was led by TK & Partners, with participation from Mesa Verde Venture Partners, The National Found

Study highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing, and durability of response across hard-to-treat tumors Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the American Association for Cancer Research (AACR) Annual Meeting

April 3, 2026 -- OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and expression solutions, today announced a strategic partnership to deliver industry-leading cell line development services for biopharmaceutical companies worldwide. This collaboration brings together OneCyte's proprietary single-cell platform for high-throughput, high-sensitivity, and high-speed clone selection with Kemp Protein

April 3, 2026 -- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087) (NSE: CIPLA) (hereafter referred to as "Cipla") today announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Cipla's Nintedanib Capsules are the generic therapeutic equivalent of Ofev®, marketed by Boehringer Ingelheim. IPF is a

April 2, 2026 -- LOTTE HOLDINGS, CO., LTD. (Tokyo, Japan; CEO: Genichi Tamatsuka, hereinafter “LOTTE HOLDINGS”) announces a strategic investment into Rakuten Medical, Inc. (hereinafter “Rakuten Medical”), a global biotechnology company developing and commercializing photoimmunotherapy-based anticancer therapies through its proprietary Alluminox ® platform. Founded in 2010 and headquartered in San Diego, CA, Rakuten Medical is currently advancing ASP-1929, its first photoimmunotherapy drug, thro

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the primary endpoint was not met In a post hoc analysis of participants (n=54) who had a history of psychiatric conditions, LPCN 1154 demonstrated nominal statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo as early as hour 12 and sustained th

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 April 02, 2026 -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76, a CLDN6

The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen demonstrated a statistically significant improvement in progression-free and overall survival compared to placebo plus paclitaxel, with or without bevacizumab Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in combi

Research published in Molecular Therapy Nucleic Acids demonstrates broad biodistribution and controlled PMP22 silencing, supporting advancement toward human trials Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy Nucleic Acids describing the safety and biodistribution impact of TVR110, a first-in-class and potential best-in-class vectorized microRNA i